Global Pulmonary Embolism Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Pulmonary Embolism Market Size

• The global pulmonary embolism market size was valued at USD 1.93 billion in 2024 and is expected to reach USD 3.66 billion by 2032, at a CAGR of 8.30% during the forecast period
• The market growth is largely fueled by the increasing prevalence of venous thromboembolism (VTE), aging populations, and growing awareness regarding early diagnosis and treatment of pulmonary embolism
• Furthermore, advancements in anticoagulant therapies, availability of novel oral anticoagulants (NOACs), and rising healthcare expenditure are fostering broader access to timely and effective treatment. These converging factors are accelerating clinical adoption, thereby significantly boosting the industry's growth

Pulmonary Embolism Market Analysis

• Pulmonary embolism (PE), a critical cardiovascular condition caused by blood clots obstructing pulmonary arteries, is becoming a major health concern globally, particularly among elderly populations and individuals with sedentary lifestyles or comorbid conditions, due to its potentially fatal outcomes and rising incidence rates
• The growing demand for effective diagnosis and treatment of PE is primarily fueled by increasing awareness, advancements in imaging technologies, and the availability of newer anticoagulant drugs offering improved safety profiles and ease of administration
• North America dominated the pulmonary embolism market with the largest revenue share of 39.2% in 2024, supported by a robust healthcare infrastructure, advanced diagnostic capabilities, and early adoption of novel therapeutics, with the U.S. leading in clinical utilization and treatment innovation for PE management
• Asia-Pacific is expected to be the fastest growing region in the pulmonary embolism market during the forecast period due to growing healthcare investment, increasing prevalence of risk factors such as obesity and cancer, and improved access to diagnostics and treatments
• Medications segment dominated the pulmonary embolism market with a market share of 64.6% in 2024, driven by the widespread use of anticoagulants as the frontline therapy and the increasing adoption of direct oral anticoagulants (DOACs) for both inpatient and outpatient care

Report Scope and Pulmonary Embolism Market Segmentation        

Pulmonary Embolism Market Trends

Rise of Direct Oral Anticoagulants (DOACs) in PE Management

• A significant and accelerating trend in the global pulmonary embolism market is the growing preference for direct oral anticoagulants (DOACs) such as rivaroxaban, apixaban, and edoxaban, over traditional vitamin K antagonists such as warfarin. This shift is largely driven by DOACs’ ease of use, predictable pharmacokinetics, and reduced need for frequent monitoring
• For instance, Xarelto (rivaroxaban) by Bayer and Eliquis (apixaban) by Bristol Myers Squibb and Pfizer are increasingly prescribed for both initial and long-term PE treatment, offering simplified dosing and a lower risk of bleeding complications
• The increased adoption of DOACs is supported by evolving clinical guidelines that recommend them as first-line therapy for most PE cases, particularly in outpatient settings. In addition, new clinical trials continue to support their efficacy and safety, further accelerating their uptake in both hospital and ambulatory care environments
• Healthcare providers are also leveraging DOACs for early discharge and home treatment protocols, reducing hospitalization time and associated costs. This contributes to enhanced patient satisfaction and better adherence to therapy
• The convenience, safety profile, and cost-effectiveness of DOACs are fundamentally reshaping the standard of care in pulmonary embolism treatment, leading to increased demand in both developed and emerging healthcare markets. Consequently, pharmaceutical companies are intensifying their efforts in DOAC development and expanding access through generics and patient assistance programs
• The trend toward DOAC dominance is expected to continue, significantly influencing treatment paradigms and driving pharmaceutical revenues in the pulmonary embolism space

Pulmonary Embolism Market Dynamics

Driver

Increasing Incidence of Venous Thromboembolism and Advancements in Diagnostics

• The global pulmonary embolism market is experiencing robust growth, largely fueled by the rising incidence of venous thromboembolism (VTE) including PE and deep vein thrombosis (DVT) due to aging populations, sedentary lifestyles, and an increasing prevalence of chronic illnesses such as cancer and cardiovascular disorders
• For instance, studies show a growing number of PE cases linked to post-surgical complications and prolonged immobilization, especially in older adults and hospitalized patients. This epidemiological trend is driving the need for early detection and effective intervention strategies
• Simultaneously, advancements in diagnostic technologies such as CT pulmonary angiography, D-dimer testing, and point-of-care ultrasound are enabling faster and more accurate diagnosis, facilitating timely treatment and improving clinical outcomes
• Furthermore, initiatives by health organizations to raise awareness about PE symptoms and prevention, especially in high-risk populations, are supporting early screening and detection efforts
• The combination of higher disease burden, technological improvements, and expanded awareness is encouraging healthcare systems to prioritize PE management, thereby boosting market growth and attracting investment from pharmaceutical and medical device companies

Restraint/Challenge

Delayed Diagnosis and High Treatment Costs in Developing Regions

• A key challenge hampering the growth of the global pulmonary embolism market is the delayed or missed diagnosis of PE, particularly in low-resource settings where access to advanced imaging tools and specialized healthcare providers remains limited
• For instance, symptoms of PE such as shortness of breath and chest pain can be nonspecific and mistaken for other conditions, leading to misdiagnosis and delayed treatment, which significantly increases morbidity and mortality risks
• Moreover, the cost of diagnostic imaging and long-term use of anticoagulants can be prohibitively high for patients in developing countries, where insurance coverage and healthcare infrastructure are often lacking
• Even when DOACs are available, their higher price compared to traditional therapies such as warfarin can limit adoption among economically constrained populations
• Addressing these challenges will require focused efforts on improving diagnostic accessibility, training healthcare professionals, expanding insurance coverage, and promoting the development of cost-effective generic medications
• These steps are critical to ensure equitable access and sustainable growth of the pulmonary embolism treatment market across diverse global regions

Pulmonary Embolism Market Scope

The market is segmented on the basis of symptoms, diagnosis, treatment, end-users, and distribution channel.

• By Symptoms

On the basis of symptoms, the pulmonary embolism market is segmented into shortness of breath, chest pain, cough, irregular heartbeat, dizziness, fever, cyanosis, and others. The shortness of breath segment dominated the market with the largest revenue share of 32.5% in 2024, as it is the most common and immediate symptom prompting patients to seek urgent medical attention. This symptom often serves as a critical indicator of PE during initial assessments, leading to its prominence in clinical diagnosis and patient awareness campaigns.

The chest pain segment is expected to witness the fastest growth rate from 2025 to 2032, fueled by increasing recognition of atypical PE presentations and enhanced emergency department screening protocols. As diagnostic awareness improves, more cases presenting with chest discomfort are being accurately diagnosed as PE, leading to increased case identification and treatment.

• By Diagnosis

On the basis of diagnosis, the pulmonary embolism market is segmented into chest X-ray, ECG, MRI, CT scan, pulmonary angiography, venography, venous ultrasound, D-dimer test, and others. The CT scan segment held the largest market revenue share of 37.8% in 2024, due to its superior sensitivity and specificity for detecting pulmonary emboli. CT pulmonary angiography (CTPA) has become the gold standard diagnostic tool in emergency settings due to rapid imaging and detailed visualization of pulmonary arteries.

The D-dimer test segment is anticipated to register the fastest growth from 2025 to 2032, attributed to its widespread use as a non-invasive, cost-effective, and quick screening method for PE risk assessment, particularly in outpatient and primary care settings.

• By Treatment

On the basis of treatment, the pulmonary embolism market is segmented into medications, mechanical devices, surgery, and others. The medications segment dominated the market with the largest share of 64.6% in 2024, driven by the central role of anticoagulants such as heparin, warfarin, and DOACs (direct oral anticoagulants) in both acute and long-term PE management. Their efficacy, ease of administration, and growing use in outpatient settings contribute significantly to this segment’s dominance.

The mechanical devices segment is projected to witness the fastest growth through 2032, driven by the increasing use of catheter-based interventions and vena cava filters for patients who are contraindicated for anticoagulation therapy.

• By End-Users

On the basis of end-users, the pulmonary embolism market is segmented into hospitals, specialty clinics, homecare, and others. The hospitals segment accounted for the largest revenue share of 51.3% in 2024, owing to the need for immediate intervention, advanced diagnostic tools, and comprehensive care infrastructure in hospital settings for acute and high-risk PE cases.

The homecare segment is expected to grow at the highest CAGR from 2025 to 2032, as DOACs facilitate outpatient treatment, enabling home-based management of stable PE patients and reducing the burden on hospital infrastructure.

• By Distribution Channel

On the basis of distribution channel, the pulmonary embolism market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others. The hospital pharmacy segment led the market with the largest share of 46.9% in 2024, as hospitals are the primary point of care for acute PE treatment and the administration of injectable anticoagulants and thrombolytics.

The online pharmacy segment is projected to witness the fastest growth over the forecast period, driven by the increasing adoption of e-commerce in healthcare, improved access to chronic PE medications such as DOACs, and rising patient preference for contactless drug delivery and digital prescription services.

Pulmonary Embolism Market Regional Analysis

• North America dominated the pulmonary embolism market with the largest revenue share of 39.2% in 2024, supported by a robust healthcare infrastructure, advanced diagnostic capabilities, and early adoption of novel therapeutics, with the U.S. leading in clinical utilization and treatment innovation for PE management
• Patients and healthcare providers in the region benefit from wide access to imaging technologies such as CT pulmonary angiography and the routine use of direct oral anticoagulants, which streamline PE management and improve outcomes
• This market leadership is further supported by strong reimbursement frameworks, ongoing clinical research, and increasing public awareness campaigns about the signs and risks of pulmonary embolism, positioning North America as a key hub for innovation and clinical excellence in PE treatment

U.S. Pulmonary Embolism Market Insight

The U.S. pulmonary embolism market captured the largest revenue share of 79% in 2024 within North America, driven by the country’s advanced healthcare infrastructure, high awareness levels, and extensive use of modern diagnostic tools such as CT pulmonary angiography. The growing incidence of venous thromboembolism due to aging populations and sedentary lifestyles is further intensifying demand for effective PE treatments. In addition, the strong presence of leading pharmaceutical companies and ongoing clinical trials are fostering innovation and accessibility in PE care across hospitals and outpatient settings.

Europe Pulmonary Embolism Market Insight

The Europe pulmonary embolism market is projected to expand at a substantial CAGR throughout the forecast period, fueled by increasing awareness of VTE-related complications and a rising aging population. The growing adoption of standardized treatment guidelines and access to novel anticoagulants are supporting regional growth. European countries are also witnessing stronger screening efforts, with healthcare systems increasingly focused on early detection and cost-effective care. Both public and private health sectors are advancing diagnostic capabilities, especially in Germany, France, and Italy.

U.K. Pulmonary Embolism Market Insight

The U.K. pulmonary embolism market is anticipated to grow at a noteworthy CAGR during the forecast period, supported by national healthcare initiatives to reduce cardiovascular disease mortality. The National Health Service (NHS) has placed emphasis on rapid diagnosis and timely intervention of PE through standardized care pathways. In addition, the increasing use of direct oral anticoagulants (DOACs) and broader access to diagnostic imaging are improving treatment outcomes and expanding market opportunities in both urban and rural settings.

Germany Pulmonary Embolism Market Insight

The Germany pulmonary embolism market is expected to expand at a considerable CAGR during the forecast period, driven by the country’s strong healthcare infrastructure and widespread access to advanced diagnostic technologies. Germany’s emphasis on preventive care and early disease detection is supporting early PE diagnosis. Furthermore, collaboration between public health authorities and pharmaceutical companies is enhancing clinical trial activity and patient access to novel therapies, making Germany a key market in the European PE treatment landscape.

Asia-Pacific Pulmonary Embolism Market Insight

The Asia-Pacific pulmonary embolism market is poised to grow at the fastest CAGR of 23.6% during the forecast period of 2025 to 2032, fueled by increasing healthcare spending, urbanization, and a rising burden of chronic diseases such as cancer and cardiovascular disorders. Countries such as China, India, and Japan are rapidly improving diagnostic infrastructure and access to anticoagulant therapies. Government-led health reforms and awareness campaigns are also playing a significant role in promoting early intervention and improving patient outcomes.

Japan Pulmonary Embolism Market Insight

The Japan pulmonary embolism market is gaining traction due to a growing elderly population, heightened health consciousness, and the adoption of advanced diagnostic modalities in hospitals. The use of non-invasive testing and DOACs is becoming more prevalent, supported by government healthcare policies aimed at managing chronic diseases. In addition, Japan's emphasis on data-driven healthcare and clinical efficiency is facilitating faster diagnosis and treatment of PE, contributing to steady market expansion.

India Pulmonary Embolism Market Insight

The India pulmonary embolism market accounted for the largest revenue share in Asia-Pacific in 2024, attributed to the country's large population base, growing healthcare awareness, and increasing access to diagnostics. Public and private initiatives to enhance healthcare access in rural and urban areas are contributing to earlier detection and management of PE cases. The availability of cost-effective treatment options, government investments in healthcare infrastructure, and domestic pharmaceutical manufacturing are key drivers propelling market growth in India.

Pulmonary Embolism Market Share

The pulmonary embolism industry is primarily led by well-established companies, including:

• Abbott (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Viatris Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Bristol-Myers Squibb Company (U.S.)
• Hikma Pharmaceuticals PLC (U.K.)
• Johnson & Johnson and its affiliates (U.S.)
• Novartis AG (Switzerland)
• Boehringer Ingelheim International GmbH. (Germany)
• Fresenius Kabi AG (Germany)
• Bayer AG (Germany)
• Lilly (U.S.)
• Merck & Co., Inc. (U.S.)
• Baxter (U.S.)
• AstraZeneca (U.K.)
• Genentech Inc. (U.S.)
• Aspen Holdings (South Africa)

What are the Recent Developments in Global Pulmonary Embolism Market?

• In July 2024, Aventus Medical announced that its Aventus Thrombectomy System received U.S. FDA clearance for the treatment of pulmonary embolism (PE). The device is designed to remove thrombus efficiently while minimizing blood loss, offering an advanced option for interventional treatment of PE patients. This clearance marks a significant milestone in expanding minimally invasive options for PE management and underscores Aventus Medical’s commitment to advancing vascular intervention technologies
• In June 2025, Endovascular Engineering Inc. announced completion of patient enrollment in the pivotal cohort of the ENGULF IDE trial, evaluating its Hēlo PE Thrombectomy System—a novel dual-action device that combines aspiration and clot disruption for pulmonary embolism treatment, designed to improve clot removal while minimizing blood loss
• In June 2025, AngioDynamics reported the first patient enrollment in the RECOVER-AV trial, evaluating the AlphaVac MMA F1885 System, a multipurpose mechanical aspiration device for acute, intermediate-risk pulmonary embolism, building on its prior FDA 510(k) clearance (April 2024) and CE Mark approval (May 2024)
• In June 2025, Penumbra, Inc. announced the completion of enrollment in the STORM-PE randomized controlled trial, which compares computer-assisted vacuum thrombectomy (CAVT) using its Lightning Flash system plus anticoagulation against anticoagulation alone for treating acute intermediate-to-high-risk PE
• In July 2024, Thrombolex, Inc. entered a strategic partnership with clinical AI leader Aidoc to enhance patient identification and accelerate enrollment for its RAPID-PE single-session registry studying the BASHIR Endovascular Catheter for acute intermediate-risk PE

SKU-55531